Skip to main content
VCbacked
Log inGet Started

Rgenta Therapeutics

Cambridge, United States

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

$8.0M raised
May 2023
Series A
BiotechnologyHealth CareMedicalOncologyPharmaceutical

Top Investors

AstraZenecaVivo CapitalHighlight CapitalMatrix Partners ChinaLilly Asia Ventures

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Rgenta Therapeutics

How much funding has Rgenta Therapeutics raised?
Rgenta Therapeutics has raised $8.0M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
Who are Rgenta Therapeutics's investors?
Rgenta Therapeutics's investors include AstraZeneca, Vivo Capital, Highlight Capital, Matrix Partners China, Lilly Asia Ventures.
Where is Rgenta Therapeutics headquartered?
Rgenta Therapeutics is headquartered in Cambridge, United States.
What does Rgenta Therapeutics do?
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
What stage is Rgenta Therapeutics at?
Rgenta Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Rgenta Therapeutics — Funding & Investors." VCBacked, May 8, 2023, https://www.vcbacked.co/company/rgenta-therapeutics. Accessed June 4, 2026.
APA
VCBacked. (2023). Rgenta Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/rgenta-therapeutics
Wikipedia (cite web)
{{cite web |title=Rgenta Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/rgenta-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong